IOVANCE BIOTHERAPEUTICS, INC. - 10-Q Filing

Iovance Biotherapeutics reports Q3 2025 financial results including revenue from contract with customers and updates on intellectual property agreements.

SEC EDGAR ·

Tickers: $IOVA

Read the full article at SEC EDGAR

More Regulatory news